DNA Script

DNA Script is a disruptive DNA synthesis company based in Le Kremlin-Bicêtre, France, that engineers biology to accelerate breakthroughs in life science and human health. The company powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

The SYNTAX System can synthesize 1-96 different oligos in parallel in a 96-well plate, with synthesis times ranging from approximately 6 hours for ninety-six 20 nt oligos to approximately 23 hours for ninety-six 120 nt oligos.

DNA Script's enzymatic DNA synthesis technology employs three core components: a highly engineered terminal deoxynucleotidyl transferase (TdT) enzyme, reversibly terminated nucleotides, and solid supports preloaded with a short, predefined initiator DNA (iDNA).

The SYNTAX System, Model STX-200, can synthesize oligos from 15-80 nt in length using the SYNTAX DNA Synthesis Kit and the SYNTAX 96 Standard Kit, or from 15-120 nt in length using the SYNTAX DNA Synthesis Kit and the SYNTAX 96 Hi-Fidelity Kit.

DNA Script was awarded up to $26M by ARPA-H in collaboration with GE HealthCare to advance cell-free DNA bioproduction through the FLASH program, supporting faster, distributed DNA manufacturing for next-generation therapies.

DNA Script expanded its access to on-demand DNA synthesis in India through a distributor agreement with Imperial Life Sciences, bringing decentralized, in-house DNA synthesis capabilities to researchers in a rapidly growing biotechnology market.

According to the company, enzymatic synthesis is water-based and accessible to any laboratory, allowing custom oligos to be produced in-house within a day, unlike chemical synthesis which may require harsh chemicals and third-party manufacturing delays.

The SYNTAX System is designed for labs requiring reliability, speed, and ease of use, offering overnight oligos ready-to-use when the lab is ready-to-go, eliminating the time delay in obtaining synthetic DNA from commercial suppliers.

DNA Script's headquarters are located at Immeuble Okabé - 67, avenue de Fontainebleau 94270 Le Kremlin-Bicêtre, France, and the company is registered as DNA Script SAS with a capital of 81,206.50 euros.

The SYNTAX System can synthesize oligos of up to 120 nt in length, while the EDS technology is also used to produce oligos of up to 500 nt in length which are available to order directly from the company.

DNA Script's enzymatic synthesis allows for the unique capability to add any desired sequence to the 3'-end of an existing, native, single-stranded DNA, a feature not possible with standard chemical methods.

DNA Script's Trustburn rating is 4.2 out of 5 from 9 reviews, with recent feedback consistently praising the reliability of synthesis, outstanding customer service, quick turnaround times, and the simplicity of the ordering process.

DNA Script targets CROs, core facilities, biotech companies, pharma companies, and governmental agencies, providing them with in-house DNA synthesis capabilities to retain control of their projects and eliminate uncertainty.

To discuss instrument costs and individual pricing terms, visitors are directed to contact DNA Script directly, as specific pricing is not publicly listed on the website.

DNA Script's technology is described as disruptive and revolutionary, aiming to eliminate the bottleneck of time delays in synthetic biology workflows by allowing labs to synthesize DNA on demand.